| Variant | Gene | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||
|---|---|---|---|---|---|---|---|---|---|---|
|
0.720 | GeneticVariation | BEFREE | Twenty-three percent of patients with V600E- and 43% of patients with K601E-mutant melanomas presented with nodal disease at diagnosis compared to just 14% of patients with BRAF wild-type tumors (P = 0.001 and 0.006, respectively). | 26643848 | 2016 |
||||
|
0.720 | GeneticVariation | BEFREE | Melanomas had p.V600E (n = 30), p.V600K (n = 4), p.K601E (n = 1), p.600-601delinsE (n = 1), or no p.V600 mutations (n = 31). | 23651150 | 2014 |
||||
|
C | 0.720 | GeneticVariation | CLINVAR | Prospective enterprise-level molecular genotyping of a cohort of cancer patients. | 25157968 | 2014 |
|||
|
C | 0.720 | GeneticVariation | CLINVAR | Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. | 22972589 | 2013 |
|||
|
C | 0.720 | GeneticVariation | CLINVAR | Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. | 22048237 | 2012 |
|||
|
C | 0.720 | GeneticVariation | CLINVAR | Improved survival with MEK inhibition in BRAF-mutated melanoma. | 22663011 | 2012 |
|||
|
C | 0.720 | GeneticVariation | CLINVAR | Improved survival with vemurafenib in melanoma with BRAF V600E mutation. | 21639808 | 2011 |
|||
|
C | 0.720 | GeneticVariation | CLINVAR | Determinants of BRAF mutations in primary melanomas. | 14679157 | 2003 |
|||
|
C | 0.720 | GeneticVariation | CLINVAR | Mutations of the BRAF gene in human cancer. | 12068308 | 2002 |